When is wegovy off patent?

Short answer: Wegovy isn’t off patent yet. It has multiple layers of protection, so real competition from generics/biosimilars depends on jurisdiction and which patents/exclusivities remain in force.

What protection is involved (US focus)?
- Biologic data exclusivity: Biologics have about 12 years of market protection from the first FDA approval of the product. Semaglutide (the active ingredient in Wegovy) first approved in the US for another approved use (OZEMPIC, for diabetes) in 2017, so this exclusivity would run roughly to 2029. A pediatric exclusivity extension can add up to 6 months, potentially pushing the effective bar to around 2030.
- Patent protection: In addition to exclusivity, there are patents on the molecule (composition of matter) and on various formulations, delivery methods, and uses. Those patent terms can extend protection into the early- to mid-2030s in the US and in other countries, depending on the specific patents and any litigation or challenges.
- Other jurisdictions: Europe, Canada, etc., have their own patent terms and regulatory exclusivities, so dates differ by country.

In practice:
- In the US, the earliest biosimilar competition would not be expected until around 2029–2030 at the earliest, and could be later if patents remain valid or litigation delays entry.
- Across other countries, timing can be similar or earlier/later depending on local patent filings and exclusivities.

If you want a precise, country-specific date, tell me which country you care about and I can summarize the current patent/exclusivity status there. I can also point you to official sources (such as the FDA’s exclusive/proprietary data listings and patent databases) for up-to-date details.